Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis
Statistically meaningful correlation between HR<sub>RFS</sub> and HR<sub>OS</sub> can assist earlier predictions of OS benefit from improvements in RFS for RCTs in resected stage II/III melanoma and provide insights for the earlier evaluation of emerging therapies. Primary model predictions should be approached with caution as nearly half of the evidence base comprised interferon-α trials.
Authors
- M Dyer
- Ellen Kasireddy (ORCID: https://orcid.org/0000-0002-2149-3671)
- John M. Kirkwood (ORCID: https://orcid.org/0000-0002-3570-4476)
- Andriy Moshyk (ORCID: https://orcid.org/0000-0003-4895-7103)
- LP Leung (ORCID: https://orcid.org/0000-0003-0219-3814)
- Murat Kurt (ORCID: https://orcid.org/0000-0001-8206-606X)
- S. Srinivasan (ORCID: https://orcid.org/0000-0001-9132-8324)
- J. Robert May
- MM. Pourrahmat
- A Qian
Institutions
- University of Pittsburgh (US)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (United Kingdom) (GB)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1016/j.iotech.2025.101042
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Celgene
- Bristol-Myers Squibb Canada